|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
22,520,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile NexImmune is a clinical-stage biotechnology company developing an approach to immunotherapy designed to employ the body's own T cells to generate a specific immune response that mimics natural biology. Co. has two product candidates: NEXI-001 in acute myeloid leukemia, and NEXI-002 in multiple myeloma. Co.'s product candidates are adoptive T cell therapies (ACTs) that contain populations of naturally occurring CD8+ T cells that recognize a defined set of disease-relevant antigen targets. In addition to its programs using the Artificial Immune Modulation (AIM) ACT adoptive cell therapy modality, Co. is also developing an off-the-shelf injectable modality, which it refers to as AIM INJ.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
500,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$768,230 |
| Total People Bought |
0 |
0 |
0 |
2 |
| Total Buy Transactions |
0 |
0 |
0 |
11 |
| Total Shares Sold |
0 |
7,825 |
7,825 |
7,825 |
| Total Sell Value |
$0 |
$16,045 |
$16,045 |
$16,045 |
| Total People Sold |
0 |
1 |
1 |
1 |
| Total Sell Transactions |
0 |
2 |
2 |
2 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Roemer Alan S. |
Director |
– • – |
2023-11-22 |
4 |
S |
$1.94 |
$7,758 |
D/D |
(3,992) |
0 |
|
- |
|
| Roemer Alan S. |
Director |
– • – |
2023-11-21 |
4 |
S |
$2.16 |
$8,287 |
D/D |
(3,833) |
3,992 |
|
- |
|
| Stover Timothy |
VP, Corporate ControllerOffice |
• – – |
2023-08-30 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
71,000 |
|
- |
|
| Jones Kristi |
President and CEO |
• • – |
2022-11-26 |
4 |
A |
$0.00 |
$0 |
D/D |
296,700 |
369,778 |
|
- |
|
| Barer Sol J |
Director |
– • – |
2022-11-17 |
4 |
B |
$0.48 |
$35,918 |
D/D |
75,000 |
1,817,814 |
2.39 |
- |
|
| Barer Sol J |
Director |
– • – |
2022-11-16 |
4 |
B |
$0.48 |
$60,300 |
D/D |
125,000 |
1,742,814 |
2.39 |
- |
|
| Verstandig Grant |
Director |
– • – |
2022-06-07 |
4 |
B |
$2.28 |
$61,385 |
D/D |
26,876 |
1,105,495 |
2.39 |
- |
|
| Verstandig Grant |
Director |
– • – |
2022-06-06 |
4 |
B |
$2.14 |
$53,538 |
D/D |
25,000 |
1,078,619 |
2.39 |
- |
|
| Verstandig Grant |
Director |
– • – |
2022-06-03 |
4 |
B |
$2.22 |
$33,374 |
D/D |
15,000 |
1,053,619 |
2.39 |
- |
|
| Verstandig Grant |
Director |
– • – |
2022-06-02 |
4 |
B |
$2.23 |
$106,683 |
D/D |
47,900 |
1,038,619 |
2.39 |
- |
|
| Barer Sol J |
Director |
– • – |
2022-06-02 |
4 |
B |
$2.22 |
$46,100 |
D/D |
20,720 |
1,617,814 |
2.39 |
- |
|
| Verstandig Grant |
Director |
– • – |
2022-06-01 |
4 |
B |
$2.38 |
$95,760 |
D/D |
40,200 |
990,719 |
2.39 |
- |
|
| Barer Sol J |
Director |
– • – |
2022-06-01 |
4 |
B |
$2.35 |
$94,160 |
D/D |
40,000 |
1,597,094 |
2.39 |
- |
|
| Verstandig Grant |
Director |
– • – |
2022-05-31 |
4 |
B |
$2.11 |
$95,118 |
D/D |
45,024 |
950,519 |
2.39 |
- |
|
| Barer Sol J |
Director |
– • – |
2022-05-31 |
4 |
B |
$2.19 |
$85,894 |
D/D |
39,280 |
1,557,094 |
2.39 |
- |
|
| Oelke Mathias |
Chief Science OfficerOfficer |
• – – |
2022-04-05 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
7,923 |
|
- |
|
| Jones Kristi |
President and CEO |
• • – |
2022-03-29 |
4 |
B |
$3.74 |
$37,400 |
D/D |
10,000 |
73,078 |
2.81 |
- |
|
| Verstandig Grant |
Director |
– • – |
2022-03-28 |
4 |
B |
$3.76 |
$71,376 |
D/D |
18,983 |
905,495 |
2.39 |
- |
|
| Verstandig Grant |
Director |
– • – |
2022-03-25 |
4 |
B |
$4.14 |
$544,915 |
D/D |
131,622 |
886,512 |
2.39 |
- |
|
| Verstandig Grant |
Director |
– • – |
2022-03-24 |
4 |
B |
$3.35 |
$133,983 |
D/D |
39,995 |
754,890 |
2.39 |
- |
|
| Barer Sol J |
Director |
– • – |
2022-03-23 |
4 |
B |
$2.67 |
$26,653 |
D/D |
10,000 |
1,517,814 |
2.39 |
- |
|
| Barer Sol J |
Director |
– • – |
2022-03-22 |
4 |
B |
$2.41 |
$72,300 |
D/D |
30,000 |
1,507,814 |
2.39 |
- |
|
| Barer Sol J |
Director |
– • – |
2022-03-21 |
4 |
B |
$2.14 |
$64,080 |
D/D |
30,000 |
1,477,814 |
2.39 |
- |
|
| Barer Sol J |
Director |
– • – |
2022-03-18 |
4 |
B |
$2.11 |
$63,210 |
D/D |
30,000 |
1,447,814 |
2.39 |
- |
|
| Roemer Alan S. |
Director |
– • – |
2021-12-21 |
4 |
OE |
$2.42 |
$245,867 |
D/D |
67,657 |
195,641 |
|
- |
|
49 Records found
|
|
Page 1 of 2 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
